Qiagen NV (NASDAQ:QGEN) Q4 2018 Earnings Conference Call Transcript

Feb 05, 2019 • 09:00 am ET


Qiagen NV (NASDAQ:QGEN) Q4 2018 Earnings Conference Call Transcript


Loading Event

Loading Transcript


Ladies and gentlemen, thank you for standing by. I am Anna, your PGI call operator. Welcome, and thank you for joining Qiagen's Conference Call to discuss the Q4 Full Year 2018 Results. At this time, all participants are in a listen-only mode. Please be advised that this call is being recorded at Qiagen's request and will be made available on their Internet site. The presentation will be followed by a question-and-answer session. (Operator Instructions)

At this time, I would like to introduce your host, John Gilardi, Vice President of Corporate Communications and Investor Relations at Qiagen. Please go ahead.

John Gilardi

Thank you, and welcome to our conference call. The speakers today are Peer Schatz, the Chief Executive Officer of Qiagen; and Roland Sackers, the Chief Financial Officer. Also joining us today is Dr. Sarah Fakih from our IR team. Please note that this call is being webcast live and will be archived in the Investor Relations section of our website at www.qiagen.com. A copy of the press release is also available on the same section.

Before we begin, let me cover our safe harbor statement. The discussion and responses to your questions on this call reflect management's view as of today, Tuesday, February 5th, 2019. We will be making statements and providing responses to your questions that state our intention, beliefs, expectations or predictions of the future. These constitute forward-looking statements for the purpose of the safe harbor provisions. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. Qiagen disclaims any intention or obligation to revise any forward-looking statements.

For more information, please refer to our filings with the US Securities and Exchange Commission. We will also be referring today to certain financial measures not prepared in accordance with generally accepted accounting principles. You can find the reconciliation of these figures to GAAP in the press release and the presentation for the call.

With that, I would like to now turn it over to Peer.

Peer Schatz

Well, thank you, John. And thank you to all of you for joining us for this call. 2018 was an important and good year for Qiagen. We delivered our performance in line with our outlook for net sales growth and exceeded our target for adjusted earnings per share. But very important is that we made big steps forward and delivered outstanding progress in developing what we believe is the most dynamic and disruptive portfolio of Sample to Insight solutions for molecular testing. This portfolio opens up vast market opportunities where our core competence can make a real difference and create value. This creates a very attractive foundation for the years to come.

Our growth initiatives are moving ahead well as we continue to execute on Qiagen's strategy as a global leader in molecular testing and want to create even greater value from this unique and differentiated portfolio. I have these key messages for you today. First, we achieved our full year target for net sales growth and exceeded our